1. HOME
  2. About Us
  3. Company Profile
  4. Consolidated Company Outline

Consolidated Company Outline

Company Name Olympus Corporation
Market Tokyo Stock Exchange, Prime Market
Stock Code ISIN: JP3201200007
Established October 12, 1919
Head Office 2951 Ishikawa-machi, Hachioji-shi, Tokyo 192-8507, Japan

Map
Share Capital 124.643 billion yen (As of March 31, 2026)
Consolidated Revenue 1,010.7 billion yen (Fiscal year ended March 31, 2026)
Consolidated Headcount 28,138 (As of March 31, 2026)

Revenue by Business Divisions/Region

Fiscal year ended March 2026: Consolidated revenue 1,010.7 billion Yen. Share of revenue by business segment: Gastrointestinal Solutions 697.4 billion Yen 69.0%, Surgical & Interventional Solutions 313.1 billion Yen 31.0%, and Other 0.2 billion Yen 0.02%.

Fiscal year ended March 2026: Consolidated revenue 1,010.7 billion Yen. Japan 103.7 billion Yen 10%, North America 405.5 billion Yen 40%, Europe 281.1 billion Yen 28%, China 82.4 billion Yen 8%, Asia and Oceania 102.6 billion Yen 10%, Other Region 35.2 billion Yen 4%.

* Note: We re-aligned our divisional structure from April 2025. The Endoscopic Solutions Division (ESD) and the Therapeutic Solutions Division (TSD) transitioned into the new divisions of Gastrointestinal Solutions Division (GIS) and Surgical & Interventional Solutions Division (SIS).
*Due to rounding, the total may not add up to 100%

Revenue and Operating Profit

Revenue and operating profit, fiscal year ended March: 2022 Revenue 868.9 billion Yen, operating profit 153.9 billion Yen. 2023 Revenue 881.9 billion Yen, operating profit 186.6 billion Yen. 2024 Revenue 925.8 billion Yen, operating profit 51.4 billion Yen. 2025 Revenue 997.3 billion Yen, operating profit 162.5 billion Yen. 2026 Revenue 1,010.7 billion yen, operating profit 97.1 billion Yen.

Pie charts showing revenue composition by business segment. GIS revenue was ¥697.4 billion, consisting of GI Endoscopy (55%), Medical Service (30%), and GI EndoTherapy (15%). SIS revenue was ¥313.1 billion, consisting of Urology (40%), Respiratory (20%), Surgical Endoscopy (20%), and Other Therapeutic Areas (20%).

Source: Financial Data for FY2026